Virtual Health is Having It's Moment

With the outbreak of COVID-19, the rapid adoption of telehealth and virtual health solutions, and the $18.5b acquisition of Livongo by Teladoc, virtual health is accelerating at a pace we’ve not seen prior. When discussing these trends and what they mean, reporters and researchers across the industry have pulled together Livongo’s primary competitors – namely Lark Health and Omada Health – to comment on what this means for the future. 

Breakdown and analysis of health tech’s largest acquisition ever — Teladoc Health’s $18B buy-out of Livongo. Leaders from Lark, Omada, and others speak on this virtual roundup.

• WATCH VIDEO

“This is a huge vote of confidence in the public markets in virtual care. For really the entire digital health sector,” Julia Hu, CEO of 10-year-old chronic condition management company Lark Health, said. Omada Health CEO Sean Duffy called the acquisition a “massive validation of the virtual care approach to chronic disease,” telling Healthcare Dive he also expects deals to ramp up down the line.

• READ MORE

“Thus, we think an acquisition of a remote monitoring firm with chronic disease management tools similar to Livongo’s could be on the horizon for MDLive… In particular, we think it’ll eye startups like Lark Health.”

• READ MORE

As a result of rapid technological advancement over the past decade, there has been an explosion in virtual diabetes management program offerings rooted in smartphone technology, connected devices for blood glucose monitoring, and remote coaching or support. 

• READ MORE

10 healthcare startups that could be M&A targets after Teladoc’s record-breaking $18.5 billion deal for Livongo – #2 – Lark Health

• READ MORE

By JULIA HU: Patients and providers need a range of services to be available virtually. Our virtual care system should embrace Remote Patient Monitoring Tools with connected devices.

• READ MORE

Virtual care may be the way of the future for treating diabetes, says Julia Hu, founder and CEO of Lark Health.

• READ MORE